Thomas W. Grunt

7.7k total citations · 1 hit paper
78 papers, 2.8k citations indexed

About

Thomas W. Grunt is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Thomas W. Grunt has authored 78 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Molecular Biology, 32 papers in Oncology and 23 papers in Cancer Research. Recurrent topics in Thomas W. Grunt's work include Retinoids in leukemia and cellular processes (15 papers), Cancer, Lipids, and Metabolism (15 papers) and Monoclonal and Polyclonal Antibodies Research (14 papers). Thomas W. Grunt is often cited by papers focused on Retinoids in leukemia and cellular processes (15 papers), Cancer, Lipids, and Metabolism (15 papers) and Monoclonal and Polyclonal Antibodies Research (14 papers). Thomas W. Grunt collaborates with scholars based in Austria, United States and Spain. Thomas W. Grunt's co-authors include Martin Offterdinger, Dietmar Pils, Anna Bachmayr-Heyda, Robert Zeillinger, Stefanie Aust, Katharina Auer, H. Huber, Nyamdelger Sukhbaatar, Agnes T. Reiner and Ildikó Mesteri and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Cell Biology and PLoS ONE.

In The Last Decade

Thomas W. Grunt

75 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Correlation of circular RNA abundance with proliferation – exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis and normal human tissues

2015 603 citations Thomas W. Grunt, Robert Zeillinger et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas W. Grunt Austria	30	2.0k	1.1k	807	318	249	78	2.8k
Mohammed A. Aleskandarany United Kingdom	36	1.7k 0.8×	1.5k 1.3×	1.6k 2.0×	315 1.0×	222 0.9×	81	3.4k
Jeffrey H. Hager United States	17	1.2k 0.6×	705 0.6×	647 0.8×	476 1.5×	175 0.7×	29	2.4k
Haili Qian China	31	1.6k 0.8×	790 0.7×	1.0k 1.3×	136 0.4×	141 0.6×	114	2.7k
Pieter J.A. Eichhorn Singapore	25	2.7k 1.3×	682 0.6×	1.3k 1.7×	191 0.6×	285 1.1×	34	3.6k
Daniel Escuín Spain	17	1.2k 0.6×	980 0.9×	671 0.8×	219 0.7×	193 0.8×	26	2.1k
François Lamoureux France	31	1.6k 0.8×	567 0.5×	830 1.0×	194 0.6×	122 0.5×	73	2.5k
Dorina Belotti Italy	26	1.3k 0.6×	779 0.7×	897 1.1×	96 0.3×	120 0.5×	43	2.4k
Prudence A. E. Scott United Kingdom	20	1.8k 0.9×	934 0.8×	885 1.1×	150 0.5×	94 0.4×	27	2.3k
Jordi Camps Spain	29	1.4k 0.7×	908 0.8×	769 1.0×	357 1.1×	87 0.3×	87	2.6k
Patricia M. McGowan Ireland	22	1.1k 0.6×	682 0.6×	1.3k 1.6×	96 0.3×	270 1.1×	33	2.3k

Countries citing papers authored by Thomas W. Grunt

Since Specialization

Citations

This map shows the geographic impact of Thomas W. Grunt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas W. Grunt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas W. Grunt more than expected).

Fields of papers citing papers by Thomas W. Grunt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas W. Grunt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas W. Grunt. The network helps show where Thomas W. Grunt may publish in the future.

Co-authorship network of co-authors of Thomas W. Grunt

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas W. Grunt. A scholar is included among the top collaborators of Thomas W. Grunt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas W. Grunt. Thomas W. Grunt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grunt, Thomas W.. (2024). Today's cancer research and treatment - highly sophisticated and molecularly targeted, yet firmly bolstered in the classical theories. Journal of Applied Biomedicine. 22(3). 123–128.

Grunt, Thomas W. & Peter Valent. (2017). Increased lipid desaturation and ovarian cancer stem cells. Translational Cancer Research. 6(3). 1 indexed citations

Schulenburg, Axel, Katharina Blatt, Sabine Cerny‐Reiterer, et al.. (2015). Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. Journal of Hematology & Oncology. 8(1). 16–16. 78 indexed citations

Grunt, Thomas W. & G Mariani. (2013). Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling. Current Cancer Drug Targets. 13(2). 188–204. 71 indexed citations

Losert, Annemarie, Daniela Lötsch, Andreas Lackner, et al.. (2012). The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Letters. 319(2). 164–172. 29 indexed citations

Atamaniuk, Johanna, Andreas Gleiß, Edit Porpaczy, et al.. (2012). Overexpression of G protein‐coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. European Journal of Clinical Investigation. 42(9). 953–960. 101 indexed citations

Vaňhara, Petr, Ahmed El‐Gazzar, Dietmar Pils, et al.. (2011). hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer. Clinical Cancer Research. 17(24). 7816–7827. 37 indexed citations

Wagner, Renate, et al.. (2011). Blockade of Fatty Acid Synthase Induces Ubiquitination and Degradation of Phosphoinositide-3-Kinase Signaling Proteins in Ovarian Cancer. Molecular Cancer Research. 9(12). 1767–1779. 60 indexed citations

Schulenburg, Axel, Harald Herrmann, Heidrun Karlic, et al.. (2010). Neoplastic stem cells: Current concepts and clinical perspectives. Critical Reviews in Oncology/Hematology. 76(2). 79–98. 27 indexed citations

10.

Grunt, Thomas W., Renate Wagner, Birgit Kainz, et al.. (2007). Upregulation of retinoic acid receptor‐β by the epidermal growth factor‐receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways. Journal of Cellular Physiology. 211(3). 803–815. 12 indexed citations

11.

Grunt, Thomas W., et al.. (2007). The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-β tumor-suppressor gene in breast cancer cells. Differentiation. 75(9). 883–890. 6 indexed citations

12.

Grunt, Thomas W., et al.. (2005). An EGF receptor inhibitor induces RAR-β expression in breast and ovarian cancer cells. Biochemical and Biophysical Research Communications. 329(4). 1253–1259. 16 indexed citations

13.

Grunt, Thomas W.. (2002). Tyrphostins and retinoids cooperate during inhibition of in vitro growth of ovarian cancer cells. Cancer Letters. 189(2). 147–156. 10 indexed citations

14.

Tang, Careen K., et al.. (1996). Involvement of heregulin-beta2 in the acquisition of the hormone-independent phenotype of breast cancer cells.. PubMed. 56(14). 3350–8. 103 indexed citations

15.

Harant, Hanna, I. J. D. Lindley, Olalekan A. Uthman, et al.. (1995). Regulation of Interleukin-8 Gene Expression by All-trans Retinoic Acid. Biochemical and Biophysical Research Communications. 210(3). 898–906. 17 indexed citations

16.

Harant, Hanna, et al.. (1993). Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription. British Journal of Cancer. 68(3). 530–536. 30 indexed citations

17.

Grunt, Thomas W., et al.. (1993). Modulation of the immunophenotype of ovarian cancer cells by N,N‐dimethylformamide and transforming growth factor‐β1. Journal of Cellular Physiology. 156(2). 358–366. 6 indexed citations

18.

Grunt, Thomas W., et al.. (1993). Different propensity for spontaneous differentiation of cell clones isolated from the human ovarian surface epithelial cell line HOC-7. Differentiation. 53(1). 45–50. 12 indexed citations

19.

Grunt, Thomas W., et al.. (1992). The differential effects of N,N‐dimethylformamide and transforming growth factor‐β1 on a human ovarian cancer cell line (HOC‐7). Journal of Cellular Physiology. 151(1). 13–22. 14 indexed citations

20.

Dittrich, Christian, P. Sevelda, Marcus Hudec, et al.. (1991). Clonogenic growth in vitro: an independent biologic prognostic factor in ovarian carcinoma.. Journal of Clinical Oncology. 9(3). 381–388. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact